LPSN – IMPORTANT DEADLINE NOTICE: The Schall Law Firm Encourages Investors in LivePerson, Inc. with Losses of $100,000 to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / May 28, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against LivePerson, Inc. (“LivePerson” or “the Company”) (NASDAQ: LPSN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

https://www.accesswire.com/users/newswire/images/718659/1schall-logo.jpg

Investors who purchased the Company’s securities between May 10, 2022 and March 16, 2023, inclusive (the “Class Period”), are encouraged to contact the firm before June 23, 2023.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm’s website at www.schallfirm.com, or by email at [email protected]

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, the Company made false and misleading statements to the market. LivePerson failed to maintain appropriate internal controls. The Company’s financial statements for the period ending September 30, 2022, failed to inform investors that its WildHealth platform had been suspended from Medicare reimbursement. Based on these facts, the Company’s public statements were false and materially misleading. When the market learned the truth about LivePerson, investors suffered damages.

Join the case to recover your losses.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:

The Schall Law Firm
Brian Schall, Esq.
310-301-3335
[email protected]
www.schallfirm.com

SOURCE: The Schall Law Firm

VIRT – INVESTOR ACTION ALERT: The Schall Law Firm Encourages Investors in Virtu Financial, Inc. with Losses of $100,000 to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / May 28, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Virtu Financial, Inc. (“Virtu” or “the Company”) (NASDAQ: VIRT) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

https://www.accesswire.com/users/newswire/images/718659/1schall-logo.jpg

Investors who purchased the Company’s securities between March 1, 2019 and April 28, 2023, inclusive (the “Class Period”), are encouraged to contact the firm before July 18, 2023.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm’s website at www.schallfirm.com, or by email at [email protected]

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, the Company made false and misleading statements to the market. Virtu failed to maintain appropriate policies and procedures related to information access barriers. The Company overstated its operational capabilities and its ability to block employees and departments from exchanging confidential data. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about Virtu, investors suffered damages.

Join the case to recover your losses.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:

The Schall Law Firm
Brian Schall, Esq.
310-301-3335
[email protected]
www.schallfirm.com

SOURCE: The Schall Law Firm

IART – ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Integra LifeSciences Holdings Corporation and Encourages Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / May 28, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Integra LifeSciences Holdings Corporation (“Integra” or “the Company”) (NASDAQ: IART) for violations of the securities laws.

https://www.accesswire.com/users/newswire/images/718659/1schall-logo.jpg

The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Integra filed a report with the SEC on May 23, 2023, stating that: “Integra LifeSciences Holdings Corporation (the “Company”), after consultation with the U.S. Food and Drug Administration (the “FDA”), initiated a voluntary global recall of all products manufactured in its Boston, Massachusetts facility (the “Boston facility”) distributed between March 1, 2018 and May 22, 2023 (the “voluntary recall”).” The Company added that it expects that the voluntary recall and manufacturing stoppage will have the greatest impact on the Tissue Technologies segment, including Private Label, and has revised guidance. For the second quarter, the Company expects reported revenues in the range of $372 million to $376 million and adjusted earnings per diluted share to be in the range of $0.55 to $0.59. While it is difficult to estimate at this time the impact of the voluntary recall for the full year, if the manufacturing stoppage continued through the remainder of 2023, the Company estimates full-year revenue and adjusted earnings per share guidance provided during the Company’s April earnings announcement would be negatively affected by approximately $60 million and $0.35, respectively. Products manufactured at the Boston facility represent approximately 5% of the Company’s consolidated revenues. The Company expects to provide updated details on its full-year guidance during its second quarter 2023 financial results conference call.”

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm’s website at www.schallfirm.com, or by email at [email protected]

The class in this case has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:

The Schall Law Firm
Brian Schall, Esq.
310-301-3335
[email protected]
www.schallfirm.com

SOURCE: The Schall Law Firm

RAIN – SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Rain Oncology Inc. and Encourages Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / May 28, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Rain Oncology Inc. (“Rain” or “the Company”) (NASDAQ: RAIN) for violations of the securities laws.

https://www.accesswire.com/users/newswire/images/718659/1schall-logo.jpg

The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Rain issued a press release on May 22, 2023, announcing topline results from its Phase 3 MANTRA trial of milademetan. The Company’s press release stated, “the trial, evaluating the efficacy, safety, and tolerability of milademetan in patients with dedifferentiated (DD) liposarcoma (LPS), did not meet its primary endpoint of progression free survival (PFS) by blinded independent central review compared to the standard of care, trabectedin” and stated that “[b]ased upon these topline data, Rain does not expect to pursue further development of milademetan in DD LPS.” Based on this news, shares of Rain fell by more than 88.7% on the same day.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm’s website at www.schallfirm.com, or by email at [email protected]

The class in this case has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:

The Schall Law Firm
Brian Schall, Esq.
310-301-3335
[email protected]
www.schallfirm.com

SOURCE: The Schall Law Firm

www.schallfirm.com

AXP – American Express stock could rally 20% from here: Morgan Stanley

American Express Company (NYSE: AXP) ended 4.0% up on Friday after a Morgan Stanley analyst said it was a top pick in financial services.

American Express stock should be worth $188

Betsy Graseck agreed that the multinational is not seeing its revenue grow as strongly as it did just after the pandemic. Still, she’s convinced that the slowdown won’t be as bad as feared.

The analyst dubs now a suitable time to build a position in American Express stock since it’s trading at a deep discount.

Amex hasn’t traded this cheaply on P/E since 2019, with a 12x P/E pricing in a sharper slowdown in growth. Yes, discretionary spend is slowing, but this is already baked into consensus estimates.

She upgraded the fintech today to “overweight” and announced a $188 price target that suggests about a 20% upside from here.

American Express missed profit estimates in Q1

Last month, the New York-based company said its profit in the first financial quarter came in shy of Street estimates.

Graseck forecasts a compound annual growth rate (CAGR) of 13% for American Express over the next year two years versus just 7.0% that its current share price is implying. Her research note also reads:

From here, American Express offers highest revenue growth, strong operating leverage, and better credit quality.

American Express stock currently pays a dividend yield of 1.53% that makes up for an additional reason to have it in your investment portfolio.

Ad

Copy expert traders easily with eToro. Invest in stocks like Tesla & Apple. Instantly trade ETFs like FTSE 100 & S&P 500. Sign-up in minutes.

10/10

77% of retail CFD accounts lose money.